Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib and Cobimetinib in Advanced BRAF V600E/K Mutant Melanoma
NCT02427893Phase 3Withdrawn
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Aug 2015
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vemurafenib, cobimetinib in melanoma, sponsored by Sidney Kimmel Comprehensive Cancer Center. Planned start Aug 2015; status: withdrawn.
02
Drugs
vemurafenibcobimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02427893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02427893.